{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0"},{"groupId":"OG001","value":"17.3"},{"groupId":"OG002","value":"0"}]}],"title":"Primary prophylaxis: Correctly treated (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13.0"},{"groupId":"OG002","value":"6.9"}]}],"title":"Primary prophylaxis:Over-treated (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3.1"},{"groupId":"OG002","value":"1.2"}]}],"title":"Secondary prophylaxis: Correctly treated (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3"},{"groupId":"OG001","value":"8.1"},{"groupId":"OG002","value":"0"}]}],"title":"Secondary prophylaxis: Under-treated (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3.5"},{"groupId":"OG002","value":"2.6"}]}],"title":"Secondary prophylaxis: Over-treated (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Primary prophylaxis: Under-treated (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"640"},{"groupId":"OG001","value":"650"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\nFN: Febrile Neutropenia; EORTC: European Organisation for Research and Treatment of Cancer","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (\\>20% chemo-associated FN risk)","id":"OG000","title":"EP2006, >20% Chemo-associated FN Risk"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (10-20% chemo-associated FN risk).","id":"OG001","title":"EP2006, 10-20% Chemo-associated FN Risk"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (\\<10% chemo-associated FN risk).","id":"OG002","title":"EP2006, <10% Chemo-associated FN Risk"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Percentage of Patients With Each Prophylaxis Decision by Chemotherapy-associated FN Risk","type":"PRIMARY","unitOfMeasure":"percentage of participants"}